Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, is set to present at the upcoming Citizens Life Sciences Conference in New York City on May 7, 2025. This event marks an important milestone for the company as it continues to advance its pipeline of innovative skin therapies. The Citizens Life Sciences Conference is a premier event that brings together industry leaders, investors, and experts in the field of life sciences to discuss the latest developments and trends in the sector. This year’s conference will take place at the New York Hilton Midtown, with participants able to access a live webcast of the event through the Verrica website.
Event Details
* Date: Wednesday, May 7, 2025
* Time: 3:00 pm ET
* Location: New York Hilton Midtown, New York
* Participants can access a live webcast of the event by clicking the link here. * The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. * A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event. As a leading dermatology therapeutics company, Verrica is committed to developing innovative treatments for skin diseases requiring medical interventions. The company’s product YCANTH® (VP-102) (cantharidin) is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The company’s pipeline includes a range of innovative therapies, including YCANTH® (VP-102) for molluscum contagiosum, as well as VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.
Upcoming Development and Commercialization
Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers. This agreement represents an important step forward for the company, as it expands its pipeline and increases its potential for growth.
Investors and Media Contact
For more information, please contact:
* Investors: John J Kirby, Interim Chief Financial Officer, [email protected](mailto:email protected)
* Media: Kevin Gardner, LifeSci Advisors
Additional Resources
* Live webcast: Click the link here to access the live webcast of the event. * Investor presentations and events: Visit the Investors/Presentations & Events section of the Verrica website at www.verrica.com. * Replay of the webcast: A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
news is a contributor at WhySkin. We are committed to providing well-researched, accurate, and valuable content to our readers.
